siRNAs targeting ANGPTL3 for mixed dyslipidemia

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Mixed dyslipidemia is a common condition characterized by elevated levels of triglycerides, LDL-C, and non-HDL-C.
• ANGPTL3 plays a key role in lipid metabolism, making it a therapeutic target for dyslipidemia.
• Current treatments for dyslipidemia have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy of solbinsiran, an siRNA targeting ANGPTL3, in adults with mixed dyslipidemia.
• To assess the impact of solbinsiran on lipid profiles, including apoB, triglycerides, LDL-C, and non-HDL-C.
• To determine the effect of solbinsiran on hepatic fat content.

Main Methods:

• The PROLONG-ANG3 trial administered two doses of solbinsiran 90 days apart.
• Participants included adults diagnosed with mixed dyslipidemia.
• Key lipid parameters and hepatic fat content were measured at day 180.

Main Results:

• Solbinsiran treatment resulted in significant reductions in apoB, triglycerides, LDL-C, and non-HDL-C concentrations.
• A notable decrease in ANGPTL3 levels was observed.
• Hepatic fat content was also significantly reduced by solbinsiran at day 180.

Conclusions:

• Two doses of solbinsiran effectively reduced lipid levels and hepatic fat content in adults with mixed dyslipidemia.
• Solbinsiran demonstrates potential as a novel therapeutic agent for managing dyslipidemia.
• Long-term studies are warranted to assess the safety and efficacy of solbinsiran in reducing atherosclerotic cardiovascular disease risk.